Home » Stocks » ProPhase Labs

ProPhase Labs, Inc. (PRPH)

Stock Price: $7.06 USD 0.05 (0.71%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed
After-hours: $7.00 -0.06 (-0.85%) Oct 20, 6:07 PM

Stock Price Chart

Key Info

Market Cap 81.93M
Revenue (ttm) 11.42M
Net Income (ttm) -1.63M
Shares Out 11.60M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $7.06
Previous Close $7.01
Change ($) 0.05
Change (%) 0.71%
Day's Open 7.11
Day's Range 6.72 - 7.24
Day's Volume 42,521
52-Week Range 1.20 - 7.49

More Stats

Market Cap 81.93M
Enterprise Value 76.05M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 11.60M
Float 8.79M
EPS (basic) -0.14
EPS (diluted) -0.14
FCF / Share 0.26
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 3.71%
Payout Ratio n/a
Shares Short 30,743
Short Ratio 0.65
Short % of Float 0.35%
Beta 0.21
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 26.97
PS Ratio 7.18
PB Ratio 5.85
Revenue 11.42M
Operating Income -1.68M
Net Income -1.63M
Free Cash Flow 3.04M
Net Cash 5.88M
Net Cash / Share 0.51
Gross Margin 22.90%
Operating Margin -14.71%
Profit Margin -14.30%
FCF Margin 26.61%
ROA -7.45%
ROE -12.48%
ROIC -15.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$8.00*
Low
8.00
Current: $7.06
High
8.00
Target: 8.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue9.8813.139.874.212.5222.0725.0322.4117.4514.50
Revenue Growth-24.76%33.03%134.59%67.04%-88.59%-11.83%11.72%28.38%20.35%-
Gross Profit2.624.781.951.000.8314.1816.6714.2511.288.83
Operating Income-3.24-1.63-3.99-3.79-2.08-7.830.42-1.10-2.74-3.59
Net Income-3.15-1.7440.59-2.87-3.60-7.830.41-1.09-2.71-3.50
Shares Outstanding11.5611.4015.5717.0816.4016.7715.8414.8414.8214.29
Earnings Per Share-0.27-0.152.59-0.17-0.22-0.470.03-0.07-0.18-0.25
Dividend Per Share0.501.00--------
Dividend Growth-50%---------
Operating Cash Flow-0.84-2.12-2.84-0.47-3.50-3.221.14-5.73-2.11-3.55
Capital Expenditures-0.23-0.1440.62-0.65-0.72-0.31-0.44-0.31-0.13-0.15
Free Cash Flow-1.07-2.2637.78-1.12-4.22-3.520.70-6.04-2.24-3.70
Cash & Equivalents1.368.2421.940.441.662.931.640.575.548.23
Total Debt---1.491.47-----
Net Cash / Debt1.368.2421.94-1.050.202.931.640.575.548.23
Assets12.2720.7433.6612.8014.8316.0617.4216.6619.0821.70
Liabilities1.044.231.816.846.005.344.825.217.858.24
Book Value11.2316.5031.855.968.8310.7212.6011.4511.2313.46
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name ProPhase Labs, Inc.
Country United States
Employees 48
CEO Ted William Karkus

Stock Information

Ticker Symbol PRPH
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: PRPH
IPO Date January 16, 1997

Description

ProPhase Labs engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ a supplement to support prostate and urinary health. In addition, the company provides contract manufacturing services for OTC healthcare and dietary supplements products. It markets its products through national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Doylestown, Pennsylvania.